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In the late eighties, several studies revealed the existence of a
third vasodilating factor next to nitric oxide (NO) and
prostacyclin (PGI2). As the action of this third factor is closely
related to smooth muscle hyperpolarization, this factor was
termed endothelium-derived hyperpolarizing factor (EDHF).
The story of its investigation is a confusing one and several
different candidate molecules and pathways have been
proposed to account for the EDHF phenomenon. Major
candidate molecules/mediators of EDHF signalling are Kþ ,
electrical coupling through gap junctions, cytochrome P450
metabolites, and endothelial small- and intermediate
Ca2þ -activated Kþ channels (SKCa and IKCa). In this mini
review, we wish to convey that EDHF is as powerful as NO
and PGI2 in terms of blood pressure regulation and that
deficiency in EDHF signalling contribute to several
cardiovascular pathologies such as hypertension, chronic
renal failure, and diabetes. In addition, we focus on recent
insight into the EDHF phenomenon provided by novel
genetic animal models, such as mice deficient of either
endothelial SKCa or IKCa and the impact of channel deficiency
on endothelial function, EDHF signalling, and arterial blood
pressure.
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THE QUEST FOR THE ENDOTHELIUM-DERIVED
HYPERPOLARIZING FACTOR
Since the pioneer work of Robert Furchgott, we have learned
that the vascular endothelium is not just a simple barrier
separating blood from tissue but in fact plays a key role in the
local control of vascular tone, adequate organ perfusion, and
systemic blood pressure by releasing vasodilating and
contracting autacoids. Next to nitric oxide (NO) and
prostacyclin (PGI2) as best defined endothelial vasodilating
autacoids, numerous studies undoubtedly revealed the
existence of a third vasodilating factor. As this NO/PGI2-
independent vasodilation was accompanied by smooth
muscle hyperpolarization, this third factor was termed
endothelium-derived hyperpolarizing factor (EDHF). On
realizing its existence in the late eighties, most people in
the field regarded EDHF as a true ‘chemical’ factor, that is a
molecule which is synthesized and released by the endothe-
lium and stimulates smooth muscle Kþ channels causing
hyperpolarization and relaxation by decreasing intracellular
Ca2þ (for review see Feletou and Vanhoutte1). However, a
single molecule or pathway could not be identified which
explained all features of EDHF signalling in different vascular
beds and species. This led to the assumption that there are
several distinct EDHFs acting alone, in parallel, or even
together. In any case and despite the fact that the ‘one and
only’ EDHF could not be identified until now, these huge
research efforts undoubtedly improved our understanding of
vessel function by identifying novel signalling molecules and
pathways. Nonetheless, the nature of the EDHF phenomenon
is still a matter of ongoing controversy.
Several candidate molecules/mediators have been
shown to act as EDHF in different tissues and species. These
include Kþ ,2 cytochrome P450 metabolites,3,4 lipoxygenase
products,5 NO itself,6 and reactive oxygen species (H2O2),
7
cyclic adenosine monophosphate,8 C-type natriuretic pep-
tide,9 and electrical coupling through myoendothelial gap
junctions.10
The relevance of each of these proposed EDHFs to EDHF-
related vasodilation and the arguments in favor or against
them were recently and excellently reviewed.1 Moreover, it
should be considered that these different concepts and
signalling pathways underlying the EDHF phenomenon may
not be mutually exclusive and may substitute in different
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regions of the vascular tree, interact, or amplify each other to
fine tune EDHF responses according to the regional needs.
In this mini review, we first wish to focus on the
importance of the EDHF system(s) in blood pressure control
and its physiological activity and defects in cardiovascular
disease states. Moreover, we wish to concentrate on recent
progresses in the field provided by novel genetic approaches.
ROLE OF EDHF IN THE REGULATION OF ARTERIAL BLOOD
PRESSURE AND CARDIOVASCULAR DISEASE STATES
When comparing the relative contribution of the major
vasodilatory systems, NO, PGI2, and EDHF to the overall
endothelium-mediated vasodilation in the arterial system,
the contribution of EDHF increases when vessel diameter
decreases.1 In contrast, the contribution of the NO system
decreases. For instance, in large conduit arteries, such as
aorta, the contribution of EDHF is small or even negligible.
In mesenteric and carotid arteries with a diameter of less than
500 mm, EDHF accounts for almost half of the total
vasodilatory response and in resistance-sized arterioles
(o100 mm) EDHF seems to be predominant.1 Although the
nature of these regional differences is still unclear, it is
possible that degree of basal myogenic tone, myoendothelial
electrical coupling, metabolic state, and/or sympathetic nerve
activity may influence the EDHF’s capability to produce a
vasodilating effect. In any case, the large contribution of
EDHF to endothelial vasodilatory mechanism in resistance-
sized arteries and arterioles, which play a critical role in blood
pressure control, makes it probable that the EDHF system is
an important determinant in regulating blood pressure. Such
experimental evidence mainly derive from in vitro and in vivo
experiments in rodents and little is known about the
contribution of EDHF in different regions of the human
vascular tree as experimentation is understandably difficult.
However, there are some reports showing that the EDHF
system (involving epoxyeicosatrienoic acids (EETs) as
potential signalling molecules and/or hyperpolarizing
Ca2þ -activated Kþ channels (KCa)) contribute to agonist-
or flow-induced endothelium-dependent vasodilation in
human mammary, radial, omental/myometrial, and gastro-
epiploic arteries.3,11–15 Moreover, it seems that the EDHF
system becomes especially active in coronary arteries of
hypertensive patients suggesting that it may serve as an
important compensatory mechanism to maintain endothe-
lium-dependent vasodilation.16,17
Moreover, there is growing evidence that the EDHF system
is disturbed in experimental genetic hypertension and other
cardiovascular disease states as well as in a variety of
knockout (KO) mice. Table 1 provides a brief overview of
the findings and the putative pathophysiological relevant
mechanisms.
For instance, the EDHF system has been reported to alter
in spontaneously hypertensive rats18,19 (and stroke-prone
spontaneously hypertensive rat20), (mREN-2)-27 transgenic
hypertensive rats,21 hypertensive Munich Wistar Fromter rats
with spontaneous albuminuria,22 uremic rats,23,24 aging,18
human hypercholesterolemia,14 restenosis,25 and in diabetic
apolipoprotein-E-deficient mice26,27 and diabetic rats.28
Although the underlying cellular basis of the defects in
EDHF signalling is still not well defined, it may involve
alterations in potassium channel expression and gap-junction
proteins or EET production (Table 1).
LESSONS FROM KO-ANIMAL MODELS
Gene-knockout strategies are certainly valuable to identify
the molecular basis of putative EDHFs and to study the
contribution of EDHF to blood pressure in living animals,
especially since most, if not all, pharmacological tools lack
specificity. However, it is well known that conventional gene
deletion strategies may bear the risk of compensation by
other similar proteins/enzymes or other pathways during
early embryonic development. Nevertheless, there are some
genetic approaches addressing explicitly EDHF and putative
EDHF pathways (Table 1).
For instance, data from transgenic mice devoid of
endothelial NO synthase (eNOS)29 as well as eNOS and
cyclooxygenase-1 (COX-1)30 suggest that the EDHF system is
capable of overcoming the loss of NO and PGI2.
31
Interestingly, this occurs more effectively in female eNOS/
/COX-1/ mice, which are normotensive, whereas male
eNOS//COX-1/ mice are hypertensive. Such a high
contribution of EDHF to vasodilatory responses and the
normal blood pressure in female eNOS//COX-1/mice
may point to the cardiovascular protective role of the EDHF
system in females.
A study using estrogen receptor (ER)a and ERb KO mice
suggests that especially ERb may contribute to the sex-related
differences in EDHF activity,32 whereas the deletion of ERa
seems to be associated with a lower NO formation in male
mice.33 Male ERb KO mice exhibit increasing blood
pressure32,34 compared with female mice despite the fact
that EDHF signalling is slightly increased in males but not in
females. The development of hypertension in aging male ERb
KO mice might be related to the loss of either inwardly-
rectifying Kþ channels, voltage-activated, or large-conduc-
tance KCa of the large-conductance KCa channel (BKCa)
type.34
It is noteworthy that such gender-specific and possibly
EDHF-related differences in blood pressure have also been
observed in soluble epoxide hydrolase KO mice.35 The soluble
epoxide hydrolase metabolizes EETs, which are considered as
putative chemical EDHFs.4 To remind the reader, the
assumption that EETs serve as EDHF is based on the
observation that EETs, preferentially 14,15- and 5,6-EET,
dilate coronary arteries of human, pigs, and rabbits,36
presumably by enhancing the open probability of BKCa
potassium channels and thus causing hyperpolarization and
relaxation of coronary smooth muscle. More recent studies
suggest that EETs contribute to EDHF signalling by
increasing endothelial Ca2þ entry and activation of en-
dothelial KCa. In soluble epoxide hydrolase KO mice, the
deficiency of soluble epoxide hydrolase greatly increased EET
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Table 1 | EDHF in cardiovascular disease
Animal model/subjects
Phenotype/carciovascular
disease/hypertension Origin/cause
Overall
endothelial
function EDHF activity Vascular bed
Proposed mechanism for altered
EDHF activity/other mechanism References
Rat models
SHR Hypertension/‘aging’ Genetic (unknown) k k Renal A/
mesenteric A
k EETs k Cx37/40 mRNA expression 18,19
SHRSP Severe hypertension Genetic (unknown) k k Mesenteric A ? 20
TGH rat Severe hypertension Transgenic (mREN-2)-27
overexpression
- m Mesenteric A k No 21
MWF rat Mild hypertension/
albuminuria
Unknown k/- k/- Coronary A/
mesenteric A
? 22
ZDF rats Diabetes type II Insulin resistance k k Small mesenteric
arteries
k KCa2.3 function/m KCa2.3 mRNA
expression
28
Chronic renal failure in
rats
Uremia/hypertension 5/6 nephrectomy k k Carotid A/small
mesenteric A
k KCa3.1/KCa2.3 /mRNA expression/
function, k hyperpolarization
23,24
Balloon catheter injury in
rats
Restenosis Endothelial ablation/
regeneration
k k Carotid A k KCa3.1/KCa2.3 mRNA expression
25
KO-mice
Diabetic apolipoprotein-
E-deficient (ApoE-KO)
mice
Diabetes/atherosclerosis Streptozotocin/ApoE gene
deletion
k/- k Small mesenteric
arteries/aorta
k KCa2.3/KCa2.2/Cx37mRNA expression
m eNOS mRNA expression
26,27
eNOSKO mice Mild hypertension eNOS gene deletion k/- m Resistance arteries/
aorta
mCOX-1 activity (males only) 29,30
eNO-KO/COX-1-KO mice Hypertension (males only) eNOS/COX-1 gene deletion k(males)
-(females)
m (females
only)
Small mesenteric
arteries/aorta
? 30
ERb-KO mice Hypertension (males only) ERb-gene deletion m (males
only)
m (males
only)
Small femoral
arteries
? 32,34
sEH-KO mice Unknown, lower blood
pressure in males
sEH-gene deletion m? m? (males
only)
m EETs 35
Connexin 40-KO mice Hypertension Cx40 gene deletion -? - Microcirculation Defective intercellular electrical
communication, abnormal vasomotion
and conducted vasodilations
37
KCa2.3
T/T mice (small-
conductance KCa channel
type 3) KCa2.3
T/T-
overexpression
Parturition defects
increased vessel diameter
Constitutive overexpression
or suppression with dietary
doxycycline
m? m? Mesenteric A m KCa2.3 mRNA expression, m resting
membrane potential in EC, diminished
basal tone
43
KCa2.3
T/T-suppression Hypertension ? ? Mesenteric A k KCa2.3 mRNA expression
43
KCa3.1-KO mice
(intermediate-
conductance KCa channel)
Hypertension KCa3.1-gene deletion k k Carotid A/
microcirculation
Endothelial dysfunction/diminished
endothelial and smooth muscle
hyperpolarization, normal conducted
vasodilations
44
Human subjects Arteriosclerosis/
hypertension
Hypercholesterolemia
genetic predisposition
classical risk factors/‘aging’
k k Large gastroepiploic
A
k KCa function?
14
Essential hypertension Unknown genetic
predisposition classical risk
factor
k m Brachial artery k No 16
ApoE, apolipoprotein-E; COX-1, cyclooxygenase-1; EC, endothelial cell; EDHF, endothelium-derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; ER, estrogen receptor; KCa2.3T/T, small-conductance KCa channel
type 3; mRNA, messenger RNA; MWF, Munich Wristar Fromter; sEH, Soluble epoxide hydrolase; SHR, spontaneously hypertensive; SHRSP, SHR-stroke prone; TGH, transgenic hypertensive; ZDF, Zucker Diabetic Fatty;
k, dysfunctional; m, upregulated.
This is a list of selected studies and thus incomplete.
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levels and caused a significant reduction in blood pressure in
male mice, but did not alter the overall lower blood pressure
in female mice.35 Thus, these data clearly support the concept
of the cardiovascular protective role of EETs, at least in male
mice.
Direct electrical coupling of endothelium and smooth
muscle have been shown to underlie EDHF signalling in a
broad variety of vascular beds from different species.1,10 This
so-called ‘myoendothelial connection’ hypothesis claims that
endothelial hyperpolarization is directly (electrically) trans-
ferred to adjacent smooth muscle. This surprisingly very
‘economic’ signal transduction pathway certainly implies that
a diffusible EDHF is no longer required. Intercellular gap-
junction channels are formed by homomeric or heteromeric
connexin subunits. In the arteries of rodents, connexin 37,
40, and 43 are expressed, from which connexin 37 and 40
seem to be predominant in endothelial cells and connexin 43
in smooth muscle cells. Consequently, pharmacological
inhibition of gap junctions and synthetic inhibitory peptides
directed against connexin 37 or 40 were found to abrogate
electrical myoendothelial communication and EDHF-
mediated vasodilation in many vessels but not in all.1,10
Mice devoid of connexin 40,37 a presumed subunit of
intercellular gap junction within the endothelium as well as
of myoendothelial gap junctions, are hypertensive and show
abnormal vasomotion and disturbed conducted vasodila-
tions. This clearly supports the concept that local intercellular
electrical communication within the vessel wall is critical for
blood pressure control, although initial EDHF signalling was
not affected in these mice. This might be explained by the
presence of (or compensation by) remaining connexins, such
as connexin 37 and, thus, multiple deletions of connexins
might be necessary to abrogate EDHF signalling. However,
double deletion of connexin 37 and 40 is complicated by
severe structural vascular abnormalities and neonatal leth-
ality,38 making it difficult to study EDHF signalling in these
mice.
Nowadays, there is broad agreement that endothelial
hyperpolarization is at first required to initiate EDHF-
mediated vasodilation in many vessels. This is based on the
observation that the inhibition of small- and intermediate-
conductance KCa channels (SKCa and IKCa), which are
actually located in the endothelium, but not inhibition of
BKCa in smooth muscle, suppress the EDHF response.
1,2
Meanwhile, endothelial KCa channels have been characterized
by electrophysiological and molecular biological means in the
endothelium of different vascular beds and species. Most
endothelial cells from humans, pigs, and rodents express IKCa
(KCa3.1 according to new nomenclature39) and the SKCa
subtype 3 (KCa2.3, commonly also known as SK3).1,25,40,41
Interestingly, a considerable expression of BKCa (KCa1.1) has
also been identified in the porcine endothelium42 and,
although in a much lesser extent, human mesenteric
endothelium.40
A recent study using transgenic KCa2.3 mice43 in which
KCa2.3 expression is either constitutively overexpressed or
suppressed by dietary doxycycline, highlighted the functional
role of this endothelial SKCa in the control of vascular tone.
In small mesenteric arteries of KCa2.3T/T mice, overexpres-
sion of endothelial SKCa caused sustained endothelial and
smooth muscle hyperpolarization and diminished myogenic-
and phenylephrine-induced tone. Moreover, external and
internal arterial diameter was greatly enhanced and the
number of branches was increased suggesting that over-
expression of endothelial SKCa also causes significant
structural changes. In contrast, suppression of SKCa by
doxycycline treatment had opposite effects on vascular tone
and increased mean arterial blood pressure by B20 mm Hg.
These findings suggest that endothelial SKCa has an impact
on the tonic-dilating influence of the endothelium on
vascular tone. However, whether EDHF signalling on agonist
stimulation is impaired in mice lacking KCa2.3, has not been
explicitly tested and thus remains unclear.
In a recent study by our group,44 we used a genetic
approach to test the importance of the other endothelial KCa,
IKCa, for EDHF signalling. In KCa3.1(IKCa)-deficient mice,
the loss of IKCa greatly reduced overall endothelial KCa
currents and, importantly, endothelial and smooth muscle
hyperpolarization responses (Figure 1). This defect was not
compensated by the other endothelial SKCa channel. In
carotid arteries, EDHF-mediated vasodilation was substan-
tially reduced leaving a residual EDHF signalling intact,
which was mediated by SKCa. Contractile responses and
endothelium-independent vasodilation were unchanged. In
the microcirculation, the defect in EDHF signalling was even
more pronounced suggesting that IKCa channels are im-
portant for generating the EDHF-mediated vasodilation in
particularly small resistance-sized arterioles. Moreover, en-
dothelium-dependent vasodilation was impaired even in the
absence of NOS and COX-1 inhibitors, thus indicating that
the defect in EDHF signalling is not compensated by the two
other systems. This also reinforces the concept that these
systems can act independently from each other. Most
strikingly, and similar to endothelial SKCa-deficient mice,
mean arterial blood pressure in KCa3.1(IKCa)-deficient mice
was increased by B14 mm Hg as determined by the tail-cuff
methods and by B7 mm Hg in 24 h telemetric measure-
ments.
Thus, these data from KCa3.1(IKCa)-deficient mice
indicate that IKCa is a crucial endothelial component of the
EDHF signalling pathway in vivo. Moreover, the finding that
this genetic manipulation of EDHF signalling has an impact
on systemic blood pressure supports the notion that the
EDHF system is important in the overall circulatory
regulation.
However, there are some questions that still need to be
addressed. In keeping with the ability of both endothelial
IKCa and SKCa channels to produce hyperpolarization, it is
surprising that one channel cannot compensate for the other.
This raises the possibility that they have (1) different
functions beyond eliciting simply hyperpolarization or (2)
one channel acts to amplify hyperpolarization, which may
148 Kidney International (2007) 72, 145–150
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allow a type of fine tuning the EDHF signal according to the
contractile state of the smooth muscle.
Regarding the first hypothesis, a recent study on cerebral
arteries proposed a functional link of endothelial SKCa
activity with NO synthesis.45 We showed that only SKCa
contributes to endothelial hyperpolarization in the presence
of NO, which may point to a direct regulation of SKCa
channels by NO, similar to effects of NO on BKCa channels,
6
whereas IKCa is not sensitive to NO (unpublished observation
by our group). However, it should be considered that a
functional link between SKCa and NO may also be mutual
because activation of SKCa (and possibly also of IKCa) may
provide the driving force for Ca2þ entry in close proximity
to eNOS, for example in a submembranous microenviron-
ment.
A recent study investigating immunohistochemically the
subcellular localization of endothelial KCa3.1/IKCa and
KCa2.3/SKCa found that SKCa immunoreactivity is predomi-
nantly at interendothelial junctions, whereas that of IKCa was
restricted to the endothelial–smooth muscle cell interface at
internal elastic lamina holes as putative myoendothelial gap-
junction sites.46 However, the functional significance of this
finding is still elusive, but indicates a role, especially of IKCa,
in myoendothelial gap-junction function or Kþ efflux and
thus EDHF signalling.
Taken together, the data from novel genetic models reveals
the functional importance of the EDHF system or at least
specific mechanistic components of EDHF signalling in the
regulation of arterial tone.
CONCLUSION
In view of recent advances in the EDHF field and despite
considerable amount of unanswered questions, the EDHF
system should be considered a fully emancipated and
powerful vasodilating system next to NO and PGI2. The
newly generated genetic models clearly indicate that this
system is more than a simple back-up system that helps to
maintain normal blood pressure and adequate organ
perfusion if one of the other systems fails. Moreover, and
in addition to well-documented endothelial dysfunction
based on reduced NO synthesis and/or NO-availability, there
is growing evidence that the EDHF system is also affected in
cardiovascular disease states, such as hypertension, diabetes,
restenosis, chronic renal failure, and during aging. Never-
theless, it is still elusive whether this type of endothelial
dysfunction is a basic cause or a consequence of disease. In
any case, components of the EDHF system such as
endothelial SKCa and IKCa may represent novel attractive
targets for the development of alternative antihypertensive
therapies.
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